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Randomized Trial of FK 50S/Prednisone vs FK 50S/ 
Azathioprine/Prednisone After Renal Transplantation: 
Preliminary Report 
R. Shapiro, M.L. Jordan, V.P. Scantlebury, J.J. Fung, C. Jensen, C. Vivas, J. McCauley, W.O. Irish, 
S. Mitchell, AJ. Oemetris, P. Randhawa, A Jain, A Tzakis, T.R. Hakala, R.L. Simmons, and T.E. Starzl 
PREVIOUS reports aboutthe use of FK 506 after renal transplantation have shown it to be associated with 
equivalent patient and graft survival, when compared with 
cyclosporine (CyA)-based regimens, and improved sec-
ondary outcomes. I- 3 These latter have included lower or 
absent chronic steroid requirements, less need for antihy-
pertensive medications, and lower serum cholesterol lev-
els. On the basis of these studies. a new randomized trial 
was begun to compare two FK 506-based regimens, with 
or without azathioprine as a third agent. Although I-year 
actuarial data are not yet available, enough information 
has been obtained to provide a preliminary summary. 
MATERIALS AND METHODS 
Between August I, 1991 and May I, 1992, 125 patients undergoing 
renal transplantation at the University of Pittsburgh were entered 
into a randomized trial comparing FK 5061prednisone and FK 
5061azathioprine/prednisone. All adults undergoing kidney trans-
plantation only, who agreed to participate in the trial, were 
eligible. Pediatric patients (8), patients receiving comitant mUltiple 
organs (8), and patients refusing or not recommended by their 
physicians to enter the trial (2) were excluded (there were, in fact, 
no refusals among the eligible patients). 
Recipient and donor characteristics are summarized in Tables I 
and 2. Thirty-two percent of the recipients were undergoing 
retransplantation; 16% of the patients had a panel reactive anti-
body level of greater than 40%. Fourteen percent of the recipients 
were over 60 years of age. Seventeen percent of the cadaveric 
kidneys were from pediatric donors 3 years or younger and we 
used en bloc. These high-risk indicators have been typical of our 
patient profiles in recent years. 
FK 506 0.15 mg/kg was given as an oral dose preoperatively. 
FK 506 0.1 mglkg/d IV as a continuous infusion was begun 
postoperatively in the recovery room and continued until the 
Table 1. Recipient Characteristics 
FK 5061 FK 506IAzalhioprinei 
Prednisone (%) Prednisone (%) Total (%) 
No. of patients 63 62 125 
Mean age (y) 42 ± 13 44± 15 43 ± 14 
Range 1!Hl6 18-78 18-78 
Age >60+ 6 (10) 12(19) 18 (14) 
First transplant 47 (75) 38 (61) 85 (68) 
Retransplant 16 (25) 24 (39) 40 (32) 
PRA >40 8 (13) 12 (19) 20 (16) 
Cadaver 50 (79) 58 (94) 108 (86) 
Living donor' 13 (21) 4 (6) 17 (14) 
Abbreviations: PAA. panel reactive antibody. 
'p < .05. 
Table 2. Donor Characteriatlcs 
FK506I FK 506IAzalhioprinei 
Prednisone Prednisone Total 
Mean age (y) 39 ± 17 41 ± 18 40 ± 18 
Range 0.3-68 0.3-67 0.3-68 
Mean cold ischemia 31.9 ± 6.7 32.4:t 8.0 32.2 ± 7.4 
time (h) 
Pediatric en bloc (%) 9 (18) 9 (16) 18 (17) 
patient was able to tolerate a diet. Oral FK 506 0.15 mglkg twice 
per day was then started. with dosage adjustment based on plasma 
levels. 
Patients received a lOOO-mg bolus of IV methylprednisolone in 
the operating room, followed by a short steroid taper from 200 to 
20 mg/d over 6 days. Further dosage reduction was individualized 
according to the patient's course. 
Azathioprine was started at a dose of 3 mglkg, both preopera-
tively and postoperatively, with dosage adjustment based on the 
white blood cell count. 
Rejection was documented histologically in almost all cases. 
Treatment generally began with a bolus of IV methylprednisolone, 
1000 mg, followed by the same recycle used for induction. Steroid 
resistance was treated with OKT3 5 mg/d x 10 days or ATGAM. 
Induction OKTI was used in one case. 
RESULTS 
The mean follow-up is 5.5 ± 2.5 months (Tables 3-5, Figs 
1,2). 
Mortality 
Of the first 125 cases, one patient has died; this was a 
50-year-old white woman 4 months after a second trans-
plant who died of colonic perforation and Pseudomonas 
sepsis. The 6-month actuarial patient survival is 99%. 
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Table 3. Results 
6 Mo Actuarial Survival 
Patient survival (%) 
Graft survival (%) 
Cadaveric (%) 
Living donor (%) 
First transplant (%) 
Retransplant (%) 
Mean serum creatinine 
Mean BUN 
Mean cholesterol 
Note: Mean follow-up was 5.5 :!: 2.5 months. 
Graft Survival 
FK 506IPrecinisone 
100 
92 
88 
100 
91 
88 
1.9 :!: 0.7mgldL 
30:!: 13 mg/dL 
199 :!: 46 mgldL 
The 6-month actuarial graft survival is 88%; 1 \0 (88%) of 
the 125 patients have functioning kidneys. Ten (8%) of 
patients are considered to have lost their grafts, 4 to 
rejection, 3 to technical reasons, 2 to disease recurrence. 
and 1 to patient death. There are 5 (4%) patients who have 
had significant rejection but may yet have recovery of graft 
function. Ninety-one percent of patients undergoing their 
first or second transplant have functioning grafts. as do 
86% of cadaveric and 100% of living donor recipients. The 
mean serum creatinine and blood urea nitrogen (BUN) are 
1.9 ± 0.7 mgldL and 30 ± 13 mgldL. No difference was 
seen between the two-drug and three-drug groups in pa-
tient or graft survival and quality of graft function. 
Rejection 
The overall incidence of rejection was 46%; 13% of pa-
tients required OKT3 or ATGAM for steroid-resistant 
rejection. Fifty-one percent of two-drug and 40% of the 
three-drug group experienced rejection (P = NS); 16% of 
the two-drug group and \0% of the three-drug group 
required OKT3 (P = NS). 
CMV 
Cytomegalovirus (CMV) infection or disease was present 
in 13% of recipients and was treated with IV ganciclovir. 
All patients routinely received high-dose acyclovir prophy-
laxis; CMV seronegative recipients of seropositive kidneys 
also received CMV immunoglobulin (Cytogam). 
Table 4. Complications 
FK 5061 FK S06lAzathioprine/ Total 
Prednisone (%) Prednisone (%) (%) 
Rejection 32 (51) 25 (40) 57 (46) 
OKT3lATGAM 10 (16) 6 (10) 16 (13) 
CMV 8 (13) 8 (13) 16 (13) 
PTLO 1 (2) 0(0) 1(1) 
New onset diabetes 7 (16) 3 (6) 10 (11) 
Note: Mean follow-up was 5.5 :!: 2.5 months. 
FK 506IAzathioprine/Prednisone 
98 
85 
84 
100 
89 
79 
1.9 :!: 0.7mgldL 
31 :!: 13 mg/dL 
195 :!: 48 mg/dL 
Initial Nonfunction 
Total 
99 
88 
86 
100 
91 
83 
1.9:!: 0.7mg/dL 
30:!: 13 mg/dL 
197:!: 47 mg/dL 
Thirty-seven percent of the recipients required dialysis at 
least once during the first week after transplantation. 
New Onset of Diabetes Mellitus 
Eleven percent of the nondiabetic recipients had at least 
temporary need for insulin after transplantation. This 
percentage appeared to be greater in the two-drug (16%) 
group than in the three-drug (6%) group, but was not 
statistically different. 
Crossover 
Twenty-six percent of the three-drug group had discontin-
uation of azathioprine at some point after transplantation. 
while 24% of the two-drug group required the addition of 
azathioprine to control persistent rejection. 
Posttransplant Lymphoproliferative Disorder (PTLD) 
PTLD was seen in the renal biopsy of one (1 %) patient on 
two-drug immunosuppression. The patient was otherwise 
asymptomatic and had a normal computed tomographic 
(CT) scan. This was treated with high-dose IV acyclovir 
and cessation of FK 506 and prednisone. 
Cholesterol 
Mean serum cholesterol was 197 ± 47 mgldL; it was 199 ± 
46 mgldL in the two-drug group and 195 ± 48 mgldL in the 
three-drug group. 
Table 5. Immunosuppression 
FK 5061 
FK Azathioprine/ 
FK506 5061Preclnisone Prednisone Total 
Mean dose 
Mgld 15.1 :!: 8.1 16.4 :!: 7.0 15.8:!: 7.6 
Mg/kgld 0.21 :!: 0.11 0.23 :!: 0.10 0.22:!:0.11 
Level ng/mL 1.0:!: 0.6 1.1 :!: 0.7 1.1 :!: 0.6 
Prednisone 
Mean dose (mg/d) 7.5:!: 5.6 8.1 :!: 5.8 7.8:!: 5.7 
Off prednisone (%) 14 (25) 11 (21) 25(23) 
Note: Mean follow-up was 5.5 :!: 2.5 months. 
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Antihypertensive Medications Steroid Requirements 
Thirty-two (29%) patients are taking no antihypertensive 
medications while 40 (36%) are on one, 27 (25%) are on 
two, 10 (9.1%) are on three, and 1 (1%) is on four 
antihypertensive medications. There was no difference 
between the two-drug and three-drug groups (Tables 6 and 
7). 
100 r-
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Twenty-five (23%) patients have been taken off pred-
nisone. Seventeen (10%) are on 2.5 to 5 mgld, while 41 
(37%) are on 7.5 to 10 mgld, and 27 (25%) are taking 12.5 
to 20 mgld (Tables 6 and 7). The mean daily prednisone 
doses are 7.8 ± 5.7 mg. The two- and three-drug groups 
behave similarly. 
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Table 6. Steroid Requirements 
FK 5061 FK 506IAzathioprinei Total 
Prednisone Dose Prednisone (%) Prednisone (%) (%) 
0 14 (25) 11 (21) 25 (23) 
OK~KM mg/d 9 (16) 8 (15) 17 (16) 
7.5-100 mg/d 21 (37) 20(38) 41 (37) 
12.5-15.0 mgld 9 (16) 9 (17) 18 (17) 
17.5-20.0 mgld 4 (7) 5 (9) 9 (8) 
FK506 
The mean FK S06 dosage is lS.8 ± 7.6 mg/d (0.22 ± 0.11 
mg/kg/d) and is similar between the two groups. The mean 
FK S06 level is 1.1 ± 0.6 ng/mL. 
DISCUSSION 
Previous studies of FK S06 in kidney transplantation have 
shown it to be equally efficacious when compared with 
CyA-based regimens. 1-3 This randomized trial was started 
to look at the effect of a third agent. azathioprine. on 
patient and graft surviVal, quality of renal function. and 
incidence of rejection, CMV. and other complications. 
Thus far. there is little evidence for a major difference 
between the two-drug and three-drug regimens, although 
there may be a trend toward less rejection and less 
diabetes in the three-drug group. The need for crossover 
from the two-drug to the three-drug group in nearly one 
fourth of the cases suggests that there is a subset of 
patients who require a third agent. There is, however, an 
equally high incidence of crossover from the three-drug to 
the two-drug group. Thus, there may be some utility for a 
third drug with FK 506 in renal transplantation; it is 
unclear whether azathioprine is the ideal candidate. 
Table 7. Antlhypenensive Requirements 
FK 5061 FK 506IAzathioprinei Total 
Number Prednisone (%j Prednisone (%) (%) 
0 18 (31) 14 (26) 32 (29) 
1 17 (30) 23 (43) 40 (36) 
2 15 (26) 12 (23) 27 (25) 
3 6 (11) 4 (8) 10 (9) 
4 1 (2) 0(0) 1 (1) 
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Overall, the results suggest an improved outcome in 
patient and graft survival, compared with the earlier expe-
rience with the drug. While the reasons are not clear, it 
may be that there is a significant learning curve with FK 
506. There is certainly a need to achieve a balance in 
dosage to avoid either rejection or nephrotoxicity. Graft 
biopsies are frequently necessary. Thus far. a relatively 
low incidence of need for OKT3. CMV, PTLD, and 
diabetes mellitus has been observed. although the inci-
dence of rejection is still significant. 
It is hoped that this encouraging report will stimulate 
interest in further trials of FK S06 in kidney transplanta-
tion. 
SUMMARY 
FK S06 was used as a primary immunosuppressive agent in 
12S cases of renal transplantation in a randomized trial 
comparing FK S06/prednisone with FK 506/azathioprinel 
prednisone. With a mean follow-up of 5.5 ± 2.S months. 
there has been a 6-month actuarial patient survival of 99% 
and graft survival of 88%. There is no difference thus far 
between the two-drug and three-drug groups, although 
there may be less rejection and diabetes in the three-drug 
group. These results suggest that FK S06 is a useful 
immunosuppressive agent in kidney transplantation. 
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